On Feb. 29, the U.S. Food and Drug Administration (FDA) announced the approval of FluMist Quadrivalent, the first influenza vaccine to contain four strains of the influenza virus, two influenza A strains and two influenza B strains. FluMist Quadrivalent is deigned to prevent seasonal influenza in people ages 2 years through 49 years. Read more.